Mammotome Launches Revolutionary In-Room MR Biopsy System and Markers for Enhanced Breast Care

Mammotome Introduces Innovations in MR-Guided Breast Biopsy

Mammotome, a prominent branch of Danaher, has recently achieved FDA clearance for groundbreaking innovations in the realm of MR-guided breast biopsy. This includes their Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System — the first system specifically tailored for in-room use alongside the MR scanner, ensuring that clinicians can closely attend to patients during procedures. The secondary innovation, HydroMARK™ Plus, serves as a site marker exclusively designed for use with the Mammotome Prima™ system, enhancing the overall biopsy process.

Advancements in Patient Care

These two new innovations aim to significantly improve the efficiency and precision of breast biopsy procedures. The Mammotome Prima™ MR system allows for better communication and coordination between clinicians directly in the MRI room, prioritizing patient comfort and focus throughout the procedure. After its successful introduction in Europe, Mammotome is set to showcase these products to U.S. clinicians at the upcoming 2026 Society of Breast Imaging (SBI) Symposium, reflecting a commitment to offering advanced solutions for breast healthcare.

One of the key features of the Mammotome Prima™ MR system is its streamlined design, which promotes simplified setup and operation for clinicians. It allows for the collection of larger tissue samples due to its enhanced vacuum strength and an 8-gauge needle. These improvements are further supported by the reduced tubing, which results in faster setup and cleanup processes. A user-friendly touchscreen interface allows healthcare providers to easily manipulate the aperture size and vacuum intensity as needed, making it a valuable tool in busy clinical environments.

HydroMARK™ Plus: A Vital Tool for Accurate Detection

Complementing the biopsy system, the HydroMARK™ Plus Breast Biopsy Site Marker is engineered for seamless integration with the Mammotome Prima™ system, ensuring precise placement during MR-guided procedures. Its advanced hydrogel technology, combined with titanium shapes, allows for high visibility under various MRI sequences without excessive blooming, which can obscure images. The design of the marker also minimizes the chances of displacement during surgical excision, a common challenge in such procedures.

Significantly, the HydroMARK™ Plus marker retains ultrasound visibility for up to 12 months. This feature is especially crucial after neoadjuvant chemotherapy, as it supports reliable localization prior to surgery, which is essential for ongoing patient care and surgical excellence. Scott Treml, Vice President and General Manager of Mammotome, emphasizes that these innovations collectively contribute to improved outcomes in the MR suite, enhancing both clinician efficiency and patient experience.

Looking Ahead

The Mammotome Prima™ MR system and HydroMARK™ Plus marker for MR are on track for rollout to U.S. clinicians this summer, with plans for availability in additional countries down the line. The developments reflect Mammotome's dedication not only to pushing the boundaries of medical technology but also to supporting clinicians and patients alike in the journey through breast care.

Furthermore, Mammotome highlights its unwavering commitment to education and support, positioning itself as an indispensable partner in breast healthcare. With these new products, Mammotome continues to empower physicians and patients, while setting a new standard in breast biopsy procedures. For more detailed information about these advancements, visit mammotome.com.